Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 5669 participants.
Also called NCT02924727
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 5,669 participants
- Sponsor
- Registry
-
NCT02924727 -
2016-002154-20
-
- Other papers using this trial's data
- Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction
- Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMI
- Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy
- Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial
- Rates of Sudden Death After Myocardial Infarction-Insights From the VALIANT and PARADISE-MI Trials
- Sex Differences in Clinical Characteristics and Outcomes After Myocardial Infarction With Low Ejection Fraction: Insights From PARADISE-MI
- The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Croatia, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, India, Israel, Italy, Mexico, Netherlands, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Singapore, Slovakia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Türkiye, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02924727. Randomized; quadruple masking; primary purpose treatment. Start 2016-12-09 (actual); primary completion 2021-02-26 (actual). Results posted on 2023-06-22.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI
- Acronym
- PARADISE-MI
- Condition
- Acute Myocardial Infarction
- Intervention (Drug)
- LCZ696 (sacubitril/valsartan)
- Intervention (Drug)
- Ramipril
- Intervention (Drug)
- Placebo of LCZ696
- Intervention (Drug)
- Placebo of ramipril
- Intervention (Drug)
- Valsartan
- Intervention (Drug)
- Placebo of valsartan
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct02924727- Content hash
63b31eddc4448069065454e77a641115add412ccf7e2d8458bc7f7ab5586c824